Minovia receives Fast Track Designation for MNV-201 in MDS

Minovia Therapeutics announces that the U.S. Food and Drug Administration has granted Fast Track Designation to the company’s lead investigational compound, MNV-201 for Myelodysplastic Syndrome, a serious age-related hematopoietic disease. This designation is in addition to the existing FDA Fast Track and Rare Pediatric Disease Designations for MNV-201 in the treatment of Pearson Syndrome, an ultra-rare and life-threatening mitochondrial disorder affecting children and for which the Company is currently conducting a Phase 2 clinical trial. The Company also recently announced entry into a definitive business combination agreement with Launch One Acquisition (LPAA) Corp. Following the expected closing of the transaction contemplated by this Business Combination Agreement, projected for late 2025, the combined company will operate as Minovia Therapeutics and trade on Nasdaq under a new ticker symbol.